Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib

Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non–small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Mok, 2009, Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Maemondo, 2010, Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530 Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non–small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation–positive non–small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non–small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 13, 1011, 10.1016/S1470-2045(12)70344-3 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440 Felip, 2014, Efficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non–small cell lung cancer (NSCLC), Ann Oncol, 25, iv426 Sequist, 2015, Rociletinib in EGFR-mutated non–small-cell lung cancer, N Engl J Med, 372, 1700, 10.1056/NEJMoa1413654 Eswarakumar, 2005, Cellular signaling by fibroblast growth factor receptors, Cytokine Growth Factor Rev, 16, 139, 10.1016/j.cytogfr.2005.01.001 Gerber, 2015, Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies, Am Soc Clin Oncol Educ Book, 147, 10.14694/EdBook_AM.2015.35.147 2012, Comprehensive genomic characterization of squamous cell lung cancers, Nature, 489, 519, 10.1038/nature11404 Paik, 2012, Multiplex testing for driver mutations in squamous cell carcinomas of the lung, J Clin Oncol, 30, 7505, 10.1200/jco.2012.30.15_suppl.7505 Weiss, 2010, Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer, Sci Transl Med, 2, 62ra93, 10.1126/scitranslmed.3001451 Zhang, 2012, Translating the therapeutic potential of AZD4547 in FGFR1-amplified non–small cell lung cancer through the use of patient-derived tumor xenograft models, Clin Cancer Res, 18, 6658, 10.1158/1078-0432.CCR-12-2694 Peifer, 2012, Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer, Nat Genet, 44, 1104, 10.1038/ng.2396 Sos, 2012, A framework for identification of actionable cancer genome dependencies in small cell lung cancer, Proc Natl Acad Sci U S A, 109, 17034, 10.1073/pnas.1207310109 Zhang, 2015, Fibroblast growth factor receptor 1 and related ligands in small-cell lung cancer, J Thorac Oncol, 10, 1083, 10.1097/JTO.0000000000000562 Lim, 2016, Efficacy and safety of dovitinib in pretreated patients with advanced squamous non–small cell lung cancer with FGFR1 amplification: a single-arm, phase 2 study, Cancer, 122, 3024, 10.1002/cncr.30135 Paik, 2017, A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers, Clin Cancer Res, 23, 5366, 10.1158/1078-0432.CCR-17-0645 Nogova, 2017, J Clin Oncol, 35, 157, 10.1200/JCO.2016.67.2048 Wynes, 2014, FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies, Clin Cancer Res, 20, 3299, 10.1158/1078-0432.CCR-13-3060 Gozgit, 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models, Mol Cancer Ther, 11, 690, 10.1158/1535-7163.MCT-11-0450 Cortes, 2012, Ponatinib in refractory Philadelphia chromosome–positive leukemias, N Engl J Med, 367, 2075, 10.1056/NEJMoa1205127 Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984 Noonan, 2016, Identifying the appropriate FISH criteria for defining MET copy number–driven lung adenocarcinoma through oncogene overlap analysis, J Thorac Oncol, 11, 1293, 10.1016/j.jtho.2016.04.033 Flacco, 2015, MYC and human telomerase gene (TERC) copy number gain in early-stage non–small cell lung cancer, Am J Clin Oncol, 38, 152, 10.1097/COC.0000000000000012 A'Hern, 2001, Sample size tables for exact single-stage phase II designs, Stat Med, 20, 859, 10.1002/sim.721 Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 Malchers, 2014, Cell-autonomous and non–cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer, Cancer Discov, 4, 246, 10.1158/2159-8290.CD-13-0323